These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

523 related items for PubMed ID: 16330288

  • 1. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
    Ryan GJ, Jobe LJ, Martin R.
    Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
    [Abstract] [Full Text] [Related]

  • 2. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
    Singh-Franco D, Robles G, Gazze D.
    Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
    [Abstract] [Full Text] [Related]

  • 3. Pramlintide for the treatment of diabetes mellitus.
    Kleppinger EL, Vivian EM.
    Ann Pharmacother; 2003 Apr; 37(7-8):1082-9. PubMed ID: 12841822
    [Abstract] [Full Text] [Related]

  • 4. The role of pramlintide for weight loss.
    Dunican KC, Adams NM, Desilets AR.
    Ann Pharmacother; 2010 Mar; 44(3):538-45. PubMed ID: 20164472
    [Abstract] [Full Text] [Related]

  • 5. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.
    Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG.
    Horm Metab Res; 2002 Sep; 34(9):504-8. PubMed ID: 12384827
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.
    Chase HP, Lutz K, Pencek R, Zhang B, Porter L.
    J Pediatr; 2009 Sep; 155(3):369-73. PubMed ID: 19464026
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical studies.
    Young A.
    Adv Pharmacol; 2005 Sep; 52():289-320. PubMed ID: 16492555
    [Abstract] [Full Text] [Related]

  • 11. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.
    Rodriguez LM, Mason KJ, Haymond MW, Heptulla RA.
    Pediatr Res; 2007 Dec; 62(6):746-9. PubMed ID: 17957149
    [Abstract] [Full Text] [Related]

  • 12. Pramlintide acetate.
    McQueen J.
    Am J Health Syst Pharm; 2005 Nov 15; 62(22):2363-72. PubMed ID: 16278328
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
    Baron AD, Kim D, Weyer C.
    Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr 15; 2(1):63-82. PubMed ID: 12477297
    [Abstract] [Full Text] [Related]

  • 18. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.
    Kolterman OG, Schwartz S, Corder C, Levy B, Klaff L, Peterson J, Gottlieb A.
    Diabetologia; 1996 Apr 15; 39(4):492-9. PubMed ID: 8778001
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pramlintide: (AC 137, AC 0137, Symlin, Tripro-Amylin).
    BioDrugs; 2003 Apr 15; 17(1):73-9. PubMed ID: 12534323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.